

---

**To:** Nova Scotia Immunization Providers  
**From:** Dr. Robert Strang, Chief Medical Officer of Health  
**Date:** December 11, 2020  
**Re:** ***Suspension Lifted for Flulaval® Tetra Vaccine Lot # KX9F7***

---

The Nova Scotia Department of Health and Wellness is advising that Flulaval® Tetra Lot # KF9X7 **can be removed from suspension** and administered. The product was suspended on November 16, 2020, pending an investigation into severe neurological adverse events following immunization in New Brunswick.

Health Canada has assessed all the available information and data provided on recent adverse events following immunization with FluLaval® Tetra Lot # KX9F7 in collaboration with the Public Health Agency of Canada (PHAC) and the manufacturer. Health Canada has also reviewed the information received from the provinces and territories to support the assessment.

Health Canada has concluded there is no causal relationship established between the vaccine in question and the reported neurological adverse events and that the known benefit/ risk profile of the product remains unchanged.

Overall, based on information we have assessed, the risk of vaccine causing serious adverse events remains low and continues to be outweighed by the benefit afforded by protection against influenza infection. Health Canada and PHAC will continue to monitor the safety of seasonal influenza vaccines.

Please report any adverse events following immunization to your local Public Health office.

Information can be found on the following link:

[https://novascotia.ca/DHW/CDPC/documents/13087\\_AdverseEventsPoster\\_En.pdf](https://novascotia.ca/DHW/CDPC/documents/13087_AdverseEventsPoster_En.pdf)

Thank you